Tras + pert mediated weak CDC in NCI-N87 cells at the highest antibody concentrations tested, and to a much lower extent than zanidatamab, but did not induce CDC-mediated cell death in any other HER2-expressing cancer cell lines (Table 1, Fig. 4a, Supplementary Fig. 7f, g). Here, ERBB2 is linked to cancer.